Cargando…

Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor

Targeted delivery of antisense oligonucleotides (ASO) to hepatocytes via the asialoglycoprotein receptor (ASGR) has improved the potency of ASO drugs ∼30-fold in the clinic (1). In order to fully characterize the effect of GalNAc valency, oligonucleotide length, flexibility and chemical composition...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmidt, Karsten, Prakash, Thazha P., Donner, Aaron J., Kinberger, Garth A., Gaus, Hans J., Low, Audrey, Østergaard, Michael E., Bell, Melanie, Swayze, Eric E., Seth, Punit P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Chemical Biology and Nucleic Acid Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389643/ https://www.ncbi.nlm.nih.gov/pubmed/28158620 http://dx.doi.org/10.1093/nar/gkx060

Ejemplares similares

Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes
por: Tanowitz, Michael, et al.
Publicado: (2017)

Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages
por: Wan, W. Brad, et al.
Publicado: (2014)

Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models
por: Kim, Youngsoo, et al.
Publicado: (2019)

Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides
por: Østergaard, Michael E, et al.
Publicado: (2020)

Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
por: Prakash, Thazha P, et al.
Publicado: (2019)

Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates
por: Østergaard, Michael E, et al.
Publicado: (2019)

Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates
por: Nair, Jayaprakash K., et al.
Publicado: (2017)

Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates
por: Janas, Maja M, et al.
Publicado: (2019)

Controlled sulfur-based engineering confers mouldability to phosphorothioate antisense oligonucleotides
por: Genna, Vito, et al.
Publicado: (2023)

Identification of metabolically stable 5′-phosphate analogs that support single-stranded siRNA activity
por: Prakash, Thazha P., et al.
Publicado: (2015)

From bench to bedside: Improving the clinical safety of GalNAc–siRNA conjugates using seed-pairing destabilization
por: Schlegel, Mark K, et al.
Publicado: (2022)

Overcoming GNA/RNA base-pairing limitations using isonucleotides improves the pharmacodynamic activity of ESC+ GalNAc-siRNAs
por: Schlegel, Mark K, et al.
Publicado: (2021)

GalNAc Conjugation Attenuates the Cytotoxicity of Antisense Oligonucleotide Drugs in Renal Tubular Cells
por: Sewing, Sabine, et al.
Publicado: (2018)

Disposition and Pharmacology of a GalNAc(3)-conjugated ASO Targeting Human Lipoprotein (a) in Mice
por: Yu, Rosie Z, et al.
Publicado: (2016)

Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2′-modifications and enhances antisense activity
por: Liang, Xue-Hai, et al.
Publicado: (2016)

Triantennary GalNAc-Functionalized Multi-Responsive Mesoporous Silica Nanoparticles for Drug Delivery Targeted at Asialoglycoprotein Receptor
por: Cordeiro, Rosemeyre, et al.
Publicado: (2022)

Overexpression of GalNAc-transferase GalNAc-T3 Promotes Pancreatic Cancer Cell Growth
por: Taniuchi, Keisuke, et al.
Publicado: (2011)

Elucidation of the Biotransformation Pathways of a Galnac(3)-conjugated Antisense Oligonucleotide in Rats and Monkeys
por: Shemesh, Colby S, et al.
Publicado: (2016)

Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression
por: Willoughby, Jennifer L.S., et al.
Publicado: (2018)

Delivery of GalNAc-Conjugated Splice-Switching ASOs to Non-hepatic Cells through Ectopic Expression of Asialoglycoprotein Receptor
por: Scharner, Juergen, et al.
Publicado: (2019)

Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2021)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Nucleoside alpha-thiotriphosphates, polymerases and the exonuclease III analysis of oligonucleotides containing phosphorothioate linkages
por: Yang, Zunyi, et al.
Publicado: (2007)

Chimeric siRNAs with chemically modified pentofuranose and hexopyranose nucleotides: altritol-nucleotide (ANA) containing GalNAc–siRNA conjugates: in vitro and in vivo RNAi activity and resistance to 5′-exonuclease
por: Kumar, Pawan, et al.
Publicado: (2020)

Integrated Assessment of Phase 2 Data on GalNAc(3)-Conjugated 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides
por: Baker, Brenda F., et al.
Publicado: (2023)

Expression of alpha-GalNAc glycoproteins by breast cancers.
por: Brooks, S. A., et al.
Publicado: (1995)

The GalNAc-T Activation (GALA) Pathway: Drivers and markers
por: Chia, Joanne, et al.
Publicado: (2019)

G-rich motifs within phosphorothioate-based antisense oligonucleotides (ASOs) drive activation of FXN expression through indirect effects
por: Wang, Feng, et al.
Publicado: (2022)

Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay
por: Gaus, Hans J, et al.
Publicado: (2019)

The Gal/GalNac lectin as a possible acetylcholine receptor in Entamoeba histolytica
por: Pacheco-Sánchez, Marisol, et al.
Publicado: (2023)

Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates
por: Brown, Christopher R, et al.
Publicado: (2020)

Molecular Recognition of GalNAc in Mucin-Type O-Glycosylation
por: Sanz-Martinez, Ignacio, et al.
Publicado: (2023)

Evidence of Gene Conversion in Genes Encoding the Gal/GalNac Lectin Complex of Entamoeba
por: Weedall, Gareth D., et al.
Publicado: (2011)

Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals
por: Seth, Punit P, et al.
Publicado: (2012)

RNase H sequence preferences influence antisense oligonucleotide efficiency
por: Kiełpiński, Łukasz J., et al.
Publicado: (2017)

Rational evolution of Cd(2+)-specific DNAzymes with phosphorothioate modified cleavage junction and Cd(2+) sensing
por: Huang, Po-Jung Jimmy, et al.
Publicado: (2015)

A new heavy lanthanide-dependent DNAzyme displaying strong metal cooperativity and unrescuable phosphorothioate effect
por: Huang, Po-Jung Jimmy, et al.
Publicado: (2015)

Integrated Assessment of the Clinical Performance of GalNAc(3)-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
por: Crooke, Stanley T., et al.
Publicado: (2019)

Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region
por: Han, Kelong, et al.
Publicado: (2022)

Role of GalNAc4S-6ST in Astrocytic Tumor Progression
por: Kobayashi, Tatsuya, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_780e2rk9i04p1purgv31bt5r7k